ASSESSMENT OF BLOOD MARKERS AFTER RADIONUCLIDE THERAPY FOR OSTEOGENIC METASTASIS OF KIDNEY AND PROSTATE CANCER . World Bulletin of Public Health, v. 12, p. 66–69, 11 Jul.2022.